Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19

While looking for a solution to treat COVID-19, the massive off-label use of several drugs in COVID-19 has generated concerns in the early phase of the pandemic because of possible arrhythmogenic effects in relation to QTc interval prolongation. Indeed, some of these drugs have been historically ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiavone, Marco, Gasperetti, Alessio, Gherbesi, Elisa, Bergamaschi, Luca, Arosio, Roberto, Mitacchione, Gianfranco, Viecca, Maurizio, Forleo, Giovanni B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556572/
https://www.ncbi.nlm.nih.gov/pubmed/35221089
http://dx.doi.org/10.1016/j.ccep.2021.10.009
Descripción
Sumario:While looking for a solution to treat COVID-19, the massive off-label use of several drugs in COVID-19 has generated concerns in the early phase of the pandemic because of possible arrhythmogenic effects in relation to QTc interval prolongation. Indeed, some of these drugs have been historically associated with QT prolongation and Torsade de Point, a potentially lethal ventricular arrhythmia, and their first-time use on a very large scale has raised several concerns in the scientific community. This work aims to summarize the underlying arrhythmogenic mechanisms related to the use of potentially QT-prolonging drugs used during the pandemic to treat COVID-19.

Ejemplares similares